PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Upadacitinib Outperforms Other Advanced Therapies After TNF Inhibitor Failure in Registry Data

upadacitinibJAK inhibitorTNF inhibitorinterleukin-6 inhibitorsabataceptrheumatoid arthritisreal-world evidenceretrospective cohortCDAItreatment sequencingOM1 registry Rheumatology / Immunology

Background Information

Upadacitinib outperforms other advanced therapies in RA remission rates.

This study guides treatment decisions for rheumatoid arthritis (RA) patients with inadequate response to tumor necrosis factor inhibitors (TNFi). 43.8% of patients on upadacitinib achieved low disease activity/remission at 12 months, compared to 23.4%-31.5% on other advanced therapies. The study provides real-world evidence favoring upadacitinib over other therapies in achieving clinical goals in RA patients post-TNFi failure. Upadacitinib may be more effective than other therapies in achieving remission in RA after TNFi use.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Charles-Schoeman C, Oelke K, Saffore CD, Kadakia A, Peng Y, Fang S, Markley G, Bergman MJ

Citation: Charles-Schoeman C, Oelke K, Saffore CD, et al. Effectiveness of Upadacitinib Versus Other Advanced Therapies in Rheumatoid Arthritis After Tumor Necrosis Factor Inhibitor Use in the United States. Rheumatology and therapy. 2026. doi:10.1007/s40744-026-00885-8

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.